Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 52, 2013, Pages

  Quoyer, Julie ^a   Janz, Jay M ^b,d   Luo, Jiansong ^c   Ren, Yong ^b,d   Armando, Sylvain ^a   Lukashova, Viktoria ^a   Benovic, Jeffrey L ^c   Carlson, Kenneth E ^b,e   Hunt III, Stephen W ^b   Bouvier, Michel ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b Anchor Therapeutics   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d PFIZER INC   (United States)

^e Ironwood Pharmaceuticals   (United States)

Author keywords

Beta arrestin; BRET; Cell signaling; Lipid anchored peptide; Protein protein interaction

Indexed keywords

ATI 2341; CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; PEPTIDE; RETINA S ANTIGEN; STROMAL CELL DERIVED FACTOR 1ALPHA; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BIOSENSOR; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84891365545     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1312515110     Document Type: Article

References (60)

1. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A (2002) Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 99(2): 643-648.
2. Janz JM, et al. (2011) Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4. J Am Chem Soc 133(40): 15878-15881.
3. O'Callaghan K, Kuliopulos A, Covic L (2012) Turning receptors on and off with intracellular pepducins: New insights into G-protein-coupled receptor drug development. J Biol Chem 287(16): 12787-12796.
4. Boire A, et al. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120(3): 303-313.
5. Cisowski J, et al. (2011) Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 179(1): 513-523.
6. Covic L, Misra M, Badar J, Singh C, Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8(10): 1161-1165.
7. Kaneider NC, et al. (2007) 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 8(12): 1303-1312.
8. Kubo S, et al. (2006) Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues. Ann N Y Acad Sci 1091: 445-459.
9. Leger AJ, et al. (2006) Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113(9): 1244-1254.
10. Zhang P, et al. (2012) Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 126(1): 83-91.
11. Kaufmann R, et al. (2009) Met receptor tyrosine kinase transactivation is involved in proteinase-activated receptor-2-mediated hepatocellular carcinoma cell invasion. Carcinogenesis 30(9): 1487-1496.
12. Sevigny LM, et al. (2011) Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc Natl Acad Sci USA 108(20): 8491-8496.
13. Sroussi HY, Lu Y, Villines D, Sun Y (2012) The down regulation of neutrophil oxidative metabolism by S100A8 and S100A9: Implication of the protease-activated receptor-2. Mol Immunol 50(1-2): 42-48.
14. Lee HY, et al. (2010) Activation of human monocytes by a formyl peptide receptor 2-derived pepducin. FEBS Lett 584(18): 4102-4108.
15. Licht T, Tsirulnikov L, Reuveni H, Yarnitzky T, Ben-Sasson SA (2003) Induction of proangiogenic signaling by a synthetic peptide derived from the second intracellular loop of S1P3 (EDG3). Blood 102(6): 2099-2107.
16. Agarwal A, et al. (2010) Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: Implications for antiangiogenic therapy. Cancer Res 70(14): 5880-5890.
17. O'Callaghan K, et al. (2012) Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 119(7): 1717-1725.
18. Tchernychev B, et al. (2010) Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc Natl Acad Sci USA 107(51): 22255-22259.
19. Choi WT, An J (2011) Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases. Exp Biol Med (Maywood) 236(6): 637-647.
20. Lusso P (2006) HIV and the chemokine system: 10 years later. EMBO J 25(3): 447-456.
21. Hoggatt J, Pelus LM (2011) Mobilization of hematopoietic stem cells from the bone marrow niche to the blood compartment. Stem Cell Res Ther 2(2):13.
22. Marquez-Curtis LA, Turner AR, Sridharan S, Ratajczak MZ, Janowska-Wieczorek A (2011) The ins and outs of hematopoietic stem cells: Studies to improve transplantation outcomes. Stem Cell Rev 7(3): 590-607.
23. Suárez-Álvarez B, López-Vázquez A, López-Larrea C (2012) Mobilization and homing of hematopoietic stem cells. Adv Exp Med Biol 741: 152-170.
24. Burger JA, Kipps TJ (2006) CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107(5): 1761-1767.
25. Kryczek I, Wei S, Keller E, Liu R, Zou W (2007) Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 292(3):C987-C995.
26. Sun X, et al. (2010) CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev 29(4): 709-722.
27. Mohty M, et al. (2011) The role of plerixafor in optimizing peripheral blood stem cell mobilization for autologous stem cell transplantation. Leukemia 25(1): 1-6.
28. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA (1996) A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184(3): 1101-1109.
29. Devine SM, et al. (2008) Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 112(4): 990-998.
30. Kean LS, et al. (2011) Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood 118(25): 6580-6590.
31. Roland J, et al. (2003) Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood 101(2): 399-406.
32. Galandrin S, Oligny-Longpré G, Bouvier M (2007) The evasive nature of drug efficacy: Implications for drug discovery. Trends Pharmacol Sci 28(8): 423-430.
33. Kenakin TP (2012) Biased signalling and allosteric machines: New vistas and challenges for drug discovery. Br J Pharmacol 165(6): 1659-1669.
34. Reiter E, Ahn S, Shukla AK, Lefkowitz RJ (2012) Molecular mechanism of β-arrestinbiased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 52: 179-197.
35. Stallaert W, Christopoulos A, Bouvier M (2011) Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors. Expert Opin Drug Discov 6(8): 811-825.
36. Whalen EJ, Rajagopal S, Lefkowitz RJ (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med 17(3): 126-139.
37. Tan W, Martin D, Gutkind JS (2006) The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem 281(51): 39542-39549.
38. Yagi H, et al. (2011) A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal 4(191):ra60.
39. Cheng ZJ, et al. (2000) beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. J Biol Chem 275(4): 2479-2485.
40. Sun Y, Cheng Z, Ma L, Pei G (2002) Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. J Biol Chem 277(51): 49212-49219.
41. Galés C, et al. (2006) Probing the activation-promoted structural rearrangements in preassembled receptor-G protein complexes. Nat Struct Mol Biol 13(9): 778-786.
42. Hamdan FF, et al. (2007) Unraveling G protein-coupled receptor endocytosis pathways using real-time monitoring of agonist-promoted interaction between betaarrestins and AP-2. J Biol Chem 282(40): 29089-29100.
43. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3(3): 193-203.
44. Black JW, Leff P (1983) Operational models of pharmacological agonism. Proc R Soc Lond B Biol Sci 220(1219): 141-162.
45. Busillo JM, et al. (2010) Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 285(10): 7805-7817.
46. Kaneider NC, Agarwal A, Leger AJ, Kuliopulos A (2005) Reversing systemic inflammatory response syndrome with chemokine receptor pepducins. Nat Med 11(6): 661-665.
47. Kenakin T, Christopoulos A (2013) Signalling bias in new drug discovery: Detection, quantification and therapeutic impact. Nat Rev Drug Discov 12(3): 205-216.
48. Urban JD, Vargas GA, von Zastrow M, Mailman RB (2007) Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 32(1): 67-77.
49. Azzi M, et al. (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100(20): 11406-11411.
50. Goupil E, et al. (2010) A novel biased allosteric compound inhibitor of parturition selectively impedes the prostaglandin F2alpha-mediated Rho/ROCK signaling pathway. J Biol Chem 285(33): 25624-25636.
51. Rajagopal S, et al. (2011) Quantifying ligand bias at seven-transmembrane receptors. Mol Pharmacol 80(3): 367-377.
52. Orsini MJ, Parent JL, Mundell SJ, Marchese A, Benovic JL (1999) Trafficking of the HIV coreceptor CXCR4: Role of arrestins and identification of residues in the c-terminal tail that mediate receptor internalization. J Biol Chem 274(43): 31076-31086.
53. Tsuji M, et al. (2013) FRET-based imaging of transbilayer movement of pepducin in living cells by novel intracellular bioreductively activatable fluorescent probes. Org Biomol Chem 11(18): 3030-3037.
54. Percherancier Y, et al. (2005) Bioluminescence resonance energy transfer reveals ligand- induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280(11): 9895-9903.
55. Wu B, et al. (2010) Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 330(6007): 1066-1071.
56. Jakubík J, Janíčková H, Randá ková A, El-Fakahany EE, Doležal V (2011) Subtype differences in pre-coupling of muscarinic acetylcholine receptors. PLoS ONE 6(11): e27732.
57. Nobles M, Benians A, Tinker A (2005) Heterotrimeric G proteins precouple with G protein-coupled receptors in living cells. Proc Natl Acad Sci USA 102(51): 18706-18711.
58. Christopherson K, 2nd, Hromas R (2001) Chemokine regulation of normal and pathologic immune responses. Stem Cells 19(5): 388-396.
59. Breton B, Lagacé M, Bouvier M (2010) Combining resonance energy transfer methods reveals a complex between the alpha2A-adrenergic receptor, Galphai1beta1gamma2, and GRK2. FASEB J 24(12): 4733-4743.
60. Campbell AK, Dormer RL (1975) Studies on free calciuminside pigeon erythrocyte 'ghosts' by using the calcium-activated luminescent protein, obelin. Biochem Soc Trans 3(5): 709-711.